CROSSROADS STRATEGIES, LLC for MERCK & CO., INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Health Issues HCR
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838/P.L.119-60), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Taxation/Internal Revenue Code TAX
Issues related to tax reform; R&D tax credit; international taxation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Trade (domestic/foreign) TRD
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.